HB3375, the Fair Prescription Drug Prices for Americans Act, would create an international reference pricing system for certain prescription drugs and biological products. It would prohibit the U.S. retail list price for covered drugs and biologics from exceeding the average retail list price in six comparator countries: Canada, France, Germany, Italy, Japan, and the United Kingdom. The bill defines covered products by reference to existing federal drug and biologics approval pathways and assigns the Secretary of Health and Human Services responsibility for calculating the benchmark prices each year.
The bill also requires manufacturers to report annual list prices for each covered product in the United States and in the six comparator countries. If a manufacturer charges more than the calculated international average, the Secretary would impose a civil monetary penalty equal to ten times the per-unit difference between the U.S. price and the foreign average, charged on each unit sold. The Secretary would be directed to issue guidance and regulations to carry out the new pricing and reporting regime.
Impact
If enacted, the bill would add a new federal price cap framework for prescription drugs and biological products and would expand HHS oversight over drug pricing data collection and enforcement. It would affect manufacturers of FDA-approved drugs and biologics by imposing annual foreign price reporting obligations and substantial penalties for exceeding the international benchmark. The measure would not amend a specific existing statute in the text, but it would operate alongside federal drug approval and public health laws by creating a new pricing standard enforced by HHS.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be presented as a consumer cost-reduction measure aimed at lowering U.S. prescription drug prices. The title and structure suggest a reform-oriented, pro-affordability posture. Because there are no transcripts or vote records available, there is no documented committee sentiment to indicate support or opposition beyond the bill’s stated purpose.
Contention
The main likely point of contention is the use of international reference pricing to set U.S. drug prices, which can be controversial because manufacturers and some policymakers argue it may reduce incentives for research, development, and launch of new therapies. Another likely issue is administrative feasibility: the bill requires HHS to gather and verify foreign pricing data annually and to enforce penalties based on cross-national comparisons. Supporters would likely emphasize lower prices for patients and payers, while opponents would likely focus on market distortion, access concerns, and the complexity of comparing list prices across countries with different reimbursement systems.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.